iTeos Therapeutics, Inc. Expected to Post Q1 2021 Earnings of ($0.45) Per Share (NASDAQ:ITOS)
iTeos Therapeutics, Inc. (NASDAQ:ITOS) – SVB Leerink issued their Q1 2021 earnings estimates for shares of iTeos Therapeutics in a research report issued to clients and investors on Tuesday, April 6th. SVB Leerink analyst D. Graybosch expects that the company will earn ($0.45) per share for the quarter. SVB Leerink has a “Outperform” rating and a $60.00 price objective on the stock.
ITOS has been the subject of a number of other reports. Zacks Investment Research upgraded shares of iTeos Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. Wedbush upped their target price on shares of iTeos Therapeutics from $46.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, March 25th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $49.40.
iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Tuesday, March 23rd. The company reported ($0.43) earnings per share for the quarter, meeting the consensus estimate of ($0.43).
Several large investors have recently added to or reduced their stakes in the company. Penserra Capital Management LLC purchased a new position in shares of iTeos Therapeutics in the 4th quarter valued at about $27,000. Morgan Stanley acquired a new position in iTeos Therapeutics in the third quarter valued at approximately $59,000. Strs Ohio purchased a new position in iTeos Therapeutics in the third quarter valued at approximately $66,000. Citigroup Inc. raised its holdings in iTeos Therapeutics by 544.1% during the fourth quarter. Citigroup Inc. now owns 3,304 shares of the company’s stock worth $112,000 after purchasing an additional 2,791 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in shares of iTeos Therapeutics in the 3rd quarter valued at $96,000. 71.07% of the stock is owned by institutional investors and hedge funds.
About iTeos Therapeutics
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial.
Read More: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.